In Silico Analysis of HA2/Mx Chimera Peptide for Developing an Adjuvanted Vaccine to Induce Immune Responses Against Influenza Viruses

Overview

Journal Adv Pharm Bull

Date 2016 Jan 22

PMID 26793608

Citations 1

Authors

Sina Soleimani

Omid Madadgar

Shahla Shahsavandi

Homayoon Mahravani

Mohsen Lotfi

Affiliations

Soon will be listed here.

Abstract

Purpose: The direct transmission of avian influenza viruses to human and increasing drug resisted strains posing new threats for public health. Therefore, development of efficient vaccines is needed to generate protective and persistent immunity to the viruses.

Methods: Three motifs of Mx protein sequence in human, mouse and poultry located in interferon induced (GTP ase) domain were candidate as biologic adjuvant for enhancing the immune responses against influenza virus. Chimera proteins composed with the conserved HA2 subunit of influenza virus and the Mx motifs named HA2/Mx were modeled and evaluated by in silico analysis includes bioinformatics algorithms in order to explore biological characteristics of these peptides.

Results: Amongst the predicted models, HA2/Mx1 peptide showed the better results following protein structures prediction, antigenic epitopes determination and model quality evaluation. Comparative homology modeling was performed with Swiss Model and the model was validated using ProSA. Epitope predictions revealed the construct could induce both B and T cell epitopes that expect a high immune response.

Conclusion: Taken together, these data indicate that the HA2/Mx1 chimera peptide can be potentiated for developing an adjuvant-fused influenza vaccine capable of stimulating effective immune response.

Citing Articles

Designing a chimeric subunit vaccine for influenza virus, based on HA2, M2e and CTxB: a bioinformatics study.

Jafari D, Malih S, Gomari M, Safari M, Jafari R, Farajollahi M BMC Mol Cell Biol. 2020; 21(1):89.

PMID: 33276715 PMC: 7716444. DOI: 10.1186/s12860-020-00334-6.

References

Kang S, Song J, Compans R . Novel vaccines against influenza viruses. Virus Res. 2011; 162(1-2):31-8. PMC: 3401575. DOI: 10.1016/j.virusres.2011.09.037. View

Riedl K, Riedl R, von Gabain A, Nagy E, Lingnau K . The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine. 2008; 26(27-28):3461-8. DOI: 10.1016/j.vaccine.2008.04.029. View

Shahsavandi S, Ebrahimi M, Sadeghi K, Mahravani H . Design of a heterosubtypic epitope-based peptide vaccine fused with hemokinin-1 against influenza viruses. Virol Sin. 2015; 30(3):200-7. PMC: 8200900. DOI: 10.1007/s12250-014-3504-0. View

Lee Y, Kim K, Ko E, Lee Y, Kim M, Kwon Y . New vaccines against influenza virus. Clin Exp Vaccine Res. 2014; 3(1):12-28. PMC: 3890446. DOI: 10.7774/cevr.2014.3.1.12. View

Grebe K, Yewdell J, Bennink J . Heterosubtypic immunity to influenza A virus: where do we stand?. Microbes Infect. 2008; 10(9):1024-9. PMC: 2584237. DOI: 10.1016/j.micinf.2008.07.002. View

Pica N, Palese P . Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med. 2013; 64:189-202. DOI: 10.1146/annurev-med-120611-145115. View

Even-Or O, Samira S, Ellis R, Kedar E, Barenholz Y . Adjuvanted influenza vaccines. Expert Rev Vaccines. 2013; 12(9):1095-108. DOI: 10.1586/14760584.2013.825445. View

Arnold K, Bordoli L, Kopp J, Schwede T . The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2005; 22(2):195-201. DOI: 10.1093/bioinformatics/bti770. View

Tomar N, De R . Immunoinformatics: an integrated scenario. Immunology. 2010; 131(2):153-68. PMC: 2967261. DOI: 10.1111/j.1365-2567.2010.03330.x. View

10.

Vigerust D, Shepherd V . Virus glycosylation: role in virulence and immune interactions. Trends Microbiol. 2007; 15(5):211-8. PMC: 7127133. DOI: 10.1016/j.tim.2007.03.003. View

11.

Russell C, Webster R . The genesis of a pandemic influenza virus. Cell. 2005; 123(3):368-71. DOI: 10.1016/j.cell.2005.10.019. View

12.

Ben-Yedidia T, Arnon R . Epitope-based vaccine against influenza. Expert Rev Vaccines. 2007; 6(6):939-48. DOI: 10.1586/14760584.6.6.939. View

13.

Liniger M, Summerfield A, Ruggli N . MDA5 can be exploited as efficacious genetic adjuvant for DNA vaccination against lethal H5N1 influenza virus infection in chickens. PLoS One. 2012; 7(12):e49952. PMC: 3515599. DOI: 10.1371/journal.pone.0049952. View

14.

Okumura Y, Takahashi E, Yano M, Ohuchi M, Daidoji T, Nakaya T . Novel type II transmembrane serine proteases, MSPL and TMPRSS13, Proteolytically activate membrane fusion activity of the hemagglutinin of highly pathogenic avian influenza viruses and induce their multicycle replication. J Virol. 2010; 84(10):5089-96. PMC: 2863848. DOI: 10.1128/JVI.02605-09. View

15.

Awate S, Babiuk L, Mutwiri G . Mechanisms of action of adjuvants. Front Immunol. 2013; 4:114. PMC: 3655441. DOI: 10.3389/fimmu.2013.00114. View

16.

Cao Y, Koh X, Dong L, Du X, Wu A, Ding X . Rapid estimation of binding activity of influenza virus hemagglutinin to human and avian receptors. PLoS One. 2011; 6(4):e18664. PMC: 3076431. DOI: 10.1371/journal.pone.0018664. View

17.

Gamblin S, Skehel J . Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem. 2010; 285(37):28403-9. PMC: 2937864. DOI: 10.1074/jbc.R110.129809. View

18.

Wang Y, Wu W, Negre N, White K, Li C, Shah P . Determinants of antigenicity and specificity in immune response for protein sequences. BMC Bioinformatics. 2011; 12:251. PMC: 3133554. DOI: 10.1186/1471-2105-12-251. View

19.

Steel J, Lowen A, Wang T, Yondola M, Gao Q, Haye K . Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio. 2010; 1(1). PMC: 2912658. DOI: 10.1128/mBio.00018-10. View

20.

Khanna M, Sharma S, Kumar B, Rajput R . Protective immunity based on the conserved hemagglutinin stalk domain and its prospects for universal influenza vaccine development. Biomed Res Int. 2014; 2014:546274. PMC: 4055638. DOI: 10.1155/2014/546274. View